Form 4: Director Gabrielle Sulzberger Acquires Eli Lilly Shares

Director Gabrielle Sulzberger acquired 5.39 shares of Eli Lilly & Co. stock through a director compensation deferral plan.

Summary

• Director Gabrielle Sulzberger acquired 5.39 shares of Eli Lilly common stock on April 20, 2026.
• The shares were acquired at a price of $919.90 per share.
• The acquisition was made in lieu of cash compensation under the Lilly Directors' Deferral Plan.
• Following this transaction, the director holds a total of 2,981.599 shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation.

Positives

• Demonstrates alignment of interest between the director and shareholders through equity ownership.
• Reflects confidence in the company's long-term value by opting for stock units over cash compensation.

Negatives

• None identified; this is a routine director compensation transaction.

Risks

• None identified; this is a standard equity acquisition filing.

Future Outlook

The shares acquired are deferred and will be settled in common stock following the director's separation from service.

Management Comments

• The shares acquired have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan.

Industry Context

StockSavvy.ai notes that director equity acquisitions via deferral plans are standard corporate governance practices, signaling internal commitment to company performance without impacting immediate cash flow.

Comparison to Industry Standards

• The use of director deferral plans is a common practice among S&P 500 companies to encourage long-term equity alignment.
• The transaction size is immaterial relative to the company's total market capitalization.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation-related transaction.

Next Steps

• No further action required; the shares will be held until the director's separation from service.

Key Dates

Keywords

Eli Lilly, LLY, Insider Trading, Form 4, Director Compensation, Equity Ownership